News25/Ratings6
News · 26 weeks39+100%
2026-03-012026-08-23
Mix2490d
- Insider11(46%)
- SEC Filings6(25%)
- Other3(13%)
- Earnings3(13%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form DEF 14A filed by Fractyl Health Inc.DEF 14A - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight MaintenanceBURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for Revita®. To register, click here. The event follows the Company’s positive one-year randomized data from the REMAIN-1 Midpoint Cohort, which showed weight maintenance one year after a single Revita procedure. The treatment effect was greatest in a pre-specified
- SECSEC Form 10-Q filed by Fractyl Health Inc.10-Q - FRACTYL HEALTH, INC. (0001572616) (Filer)
- SECFractyl Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health Reports Second Quarter 2026 Financial Results and Business UpdatesOne-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026 Cash runway guidance into early 2027, beyond anticipat
- PRFractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a clinical-stage m
- PRFractyl Health to Participate in Upcoming Investor EventsBURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: BTIG Virtual Biotechnology ConferenceFormat: One-on-one meetingsDates: July 28 – 29, 2026 Needham & Company MedTech & Diagnostics 1x1 ConferenceFormat: One-on-one meetingsDates: August 10 – 11, 2026 Canaccord Genuity 46th Annual Growth ConferenceFormat: Fireside chat and
- SECFractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 DiscontinuationUp to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 Company to host investor webcast today at 8:00 a.m. ET BURLINGTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced positive one-year results from its
- INSIDERDirector Royan Ajay bought $19,596 worth of shares (23,000 units at $0.85), increasing direct ownership by 128% to 40,901 units (SEC Form 4)4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- SECFractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- INSIDERChief Executive Officer Rajagopalan Harith bought $18,252 worth of shares (25,000 units at $0.73), increasing direct ownership by 5% to 540,557 units (SEC Form 4)4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERDirector Sheffield Ian bought $25,529 worth of shares (35,000 units at $0.73) (SEC Form 4)4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERSEC Form 4 filed by Director Meanwell Clive4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERSEC Form 4 filed by Director Barnes Kelly Ann4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERSEC Form 4 filed by Director Elia Marc4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERSEC Form 4 filed by Director Thompson Christopher Charles4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERSEC Form 4 filed by Director Royan Ajay4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERSEC Form 4 filed by Director Conaway Samuel4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERDirector Bradley William bought $50,329 worth of shares (68,493 units at $0.73), increasing direct ownership by 425% to 84,622 units (SEC Form 4)4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- INSIDERChief Financial Officer Smith Weber Lara bought $13,708 worth of shares (20,000 units at $0.69) (SEC Form 4)4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)
- SECFractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)
- PRFractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® ProcedureParticipants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure 5.3% mean weight change observed with Revita (n=15); published third-party studies after GLP-1 withdrawal alone have shown ~15% weight regain at similar time points 33% of patients continued to lose further weight one year after discontinuing a GLP-1 Next anticipated Revita® clinical data readouts are one-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 and topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 BURLINGTON, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or
- PRFractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial StrategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced the appointment of Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy. Mr. Zumdahl served as Vice President of Global Health Economics, Market Access, and Government Affairs at Inari Medical, where he led the function through the company's growth and 2025 acquisition by Stryker. He joins Fractyl as the Company prepares for the anticipated REMAIN-1 Pivotal Cohort topline readout in early Q4 2026 and a potenti
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)
GUTS FAQ
6 questionsWhere does GUTS stock trade?
Fractyl Health Inc. (GUTS) is listed on NASDAQ.What sector and industry is GUTS in?
Fractyl Health Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Fractyl Health Inc. go public?
Fractyl Health Inc. (GUTS) completed its IPO in 2024.What are analysts saying about GUTS?
Fractyl Health Inc. has had 6 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $200.00 price target on 2026-01-30.What companies are similar to GUTS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare GUTS side-by-side with any of them on Quantisnow.How can I track GUTS on Quantisnow?
Quantisnow aggregates Fractyl Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GUTS to receive live email and push alerts on every new disclosure.